Two hundred and four patients with biopsy-proven HBsAg-positive chronic active hepatitis were treated for at least 2 years with azathioprine, prednisolone or a combination of both, or were untreated. Prevalences of HBeAg, anti-HBe, and anti-HBc were 26, 58, and loo%, respectively. Criteria for impro
Prevalence of hbeag and anti-hbe in chronic active hepatitis, cirrhosis and primary hepatocellular carcinoma in korea
β Scribed by Chung-Yong Kim; Soon-Kee Bae; Hie-Won L. Hann; W. Thomas London; Baruch S. Blumberg
- Publisher
- John Wiley and Sons
- Year
- 1985
- Tongue
- English
- Weight
- 326 KB
- Volume
- 5
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
β¦ Synopsis
The prevalence of HBeAg was studied in Korean patients with chronic active hepatitis, cirrhosis and primary hepatocellular carcinoma. There is an independent association of HBeAg prevalence with age and diagnosis. These findings are discussed in terms of a developmental model for primary hepatocellular carcinoma which could explain the lower frequency of HBeAg in the cancer cases.
π SIMILAR VOLUMES
## Abstract To investigate the relationship between viral factors and the development of chronic hepatitis B, the entire hepatitis B virus (HBV) genome of chronic carriers at different disease stages were analyzed. Eighty genotype C HBV carriers including 12 hepatitis B e antigen (HBeAg) positive a
sis. Also, the activity of fetal P3 and P4 promoters was Increased prevalence of hepatitis C virus (HCV) infechigher in the nontumorous than in the tumorous area tion has been found in patients with hepatocellular carof the liver of HCC patients. The expression of IGF-II cinoma (HCC). The expression
The age-specific prevalence of hepatitis B e antigen (HBeAg) and its antibody (anti-HBe) were studied by radioimmunoassay, and compared in a large series of patients with chronic hepatitis B virus (HBV) infection, including 268 asymptomatic carriers, 389 chronic hepatitis, 114 liver cirrhosis, and 2
Objective: To prospectively determine the prevalence and annual incidence of hepatocellular carcinoma in hepatitis B carriers in a heterogeneous urban North American population and to assess the diagnostic accuracy of tests used for screening for this cancer. Design: Prospective cohort study of 1,06